Financial
FY2025 revenue $2.09bn (+6.0%); adjusted operating margin 29.5%.
Net sales rounded in release; diluted EPS $1.94. Full GAAP figures in annual report.
QIAGEN
HQ Netherlands · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Strong
Customer rating
No reviews yet
Financial health
Band: StrongListed: QGEN
FY2025 revenue $2.09bn (+6.0%); adjusted operating margin 29.5%.
Net sales rounded in release; diluted EPS $1.94. Full GAAP figures in annual report.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$2.1bn | +6.0% | — | — | QIAGEN |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Aug 2026: QIAGEN named Jon Pratt CEO from 1 Sep 2026, replacing Thierry Bernard, while its supervisory board continued a strategic review with outside advisers. In Mar 2025 QIAGEN began patent litigation to defend its QuantiFERON TB test.
Cyber & information governance
No data breaches, cyber incidents or regulator actions involving QIAGEN found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Mar 2025: QIAGEN initiated an FDA Class 2 recall of one lot of QIAstat-Dx Respiratory Panel Plus cartridges (US distribution) after faulty cartridges were found that could give false results; customers were offered free replacements.
Contract performance
Nov 2025: Defra awarded QIAGEN Ltd a £3.1m contract for QIAGEN reagents to March 2028, called off from an NHS Supply Chain framework. No customer disputes or terminations found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.